AHA Scientific Sessions 2026 · ATTAIN-OSA
Takatoshi Kasai
Cardiology
Although the reduction in AHI observed with the oral GLP-1 receptor agonist orforglipron in the ATTAIN-OSA trial did not reach the magnitude of the effect seen with subcutaneous injections of the GIP/GLP-1 receptor agonist tirzepatide, the oral nature of the former suggests that a broader range of patients could potentially benefit.
Orforglipron for Obstructive Sleep Apnea
JAMAAtul Malhotra et al.